Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Hunsaker

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Biorxiv : the Preprint Server for Biology|August 16, 2024
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Cancers|August 29, 2024
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in MelanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Neuro-Oncology|May 9, 2020
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoproteinHolger Fischer, Mohammed Ullah, Cecile C de la Cruz, et al.
Cancer Research|November 10, 2012
An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancerMark L McCleland, Adam S Adler, Yonglei Shang, et al.
Cancer Cell|October 10, 2018
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant TumorsIvana Yen, Frances Shanahan, Mark Merchant, et al.
Cell Metabolism|July 26, 2018
Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell StateAnneleen Daemen, Bonnie Liu, Kyung Song, et al.
Cancer Research|July 3, 2025
RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted TherapyAshley V DiMarco, Mirunalini Ravichandran, Jeff Lau, et al.
Bioorganic & Medicinal Chemistry Letters|September 10, 2013
Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenaseBenjamin P Fauber, Peter S Dragovich, Jinhua Chen, et al.
Journal of Medicinal Chemistry|May 1, 2009
A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora BIgnacio Aliagas-Martin, Dan Burdick, Laura Corson, et al.
Plos One|January 26, 2018
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Biorxiv : the Preprint Server for Biology|August 16, 2024
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Cancers|August 29, 2024
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in MelanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Neuro-Oncology|May 9, 2020
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoproteinHolger Fischer, Mohammed Ullah, Cecile C de la Cruz, et al.
Cancer Research|November 10, 2012
An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancerMark L McCleland, Adam S Adler, Yonglei Shang, et al.
Cancer Cell|October 10, 2018
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant TumorsIvana Yen, Frances Shanahan, Mark Merchant, et al.
Cell Metabolism|July 26, 2018
Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell StateAnneleen Daemen, Bonnie Liu, Kyung Song, et al.
Cancer Research|July 3, 2025
RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted TherapyAshley V DiMarco, Mirunalini Ravichandran, Jeff Lau, et al.
Bioorganic & Medicinal Chemistry Letters|September 10, 2013
Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenaseBenjamin P Fauber, Peter S Dragovich, Jinhua Chen, et al.
Journal of Medicinal Chemistry|May 1, 2009
A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora BIgnacio Aliagas-Martin, Dan Burdick, Laura Corson, et al.
Plos One|January 26, 2018
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Pageof 2